Sarepta Therapeutics, Inc.
SRPT
$105.56
-$2.11-1.96%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 658.41M | 467.17M | 362.93M | 413.46M | 396.78M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 658.41M | 467.17M | 362.93M | 413.46M | 396.78M |
| Cost of Revenue | 332.26M | 316.17M | 224.24M | 250.96M | 239.69M |
| Gross Profit | 326.16M | 151.00M | 138.70M | 162.51M | 157.09M |
| SG&A Expenses | 163.87M | 128.20M | 138.80M | 127.00M | 131.70M |
| Depreciation & Amortization | 601.00K | 602.00K | 601.00K | 601.00K | 763.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 496.73M | 444.98M | 363.63M | 378.56M | 372.16M |
| Operating Income | 161.68M | 22.20M | -701.00K | 34.91M | 24.63M |
| Income Before Tax | 171.74M | 34.01M | 13.58M | 41.45M | 40.37M |
| Income Tax Expenses | 12.69M | 395.00K | 7.12M | 5.33M | -5.28M |
| Earnings from Continuing Operations | 159.05M | 33.61M | 6.46M | 36.12M | 45.66M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 159.05M | 33.61M | 6.46M | 36.12M | 45.66M |
| EBIT | 161.68M | 22.20M | -701.00K | 34.91M | 24.63M |
| EBITDA | 172.14M | 32.00M | 8.02M | 43.65M | 36.00M |
| EPS Basic | 1.65 | 0.35 | 0.07 | 0.38 | 0.49 |
| Normalized Basic EPS | 1.07 | 0.14 | 0.02 | 0.26 | 0.19 |
| EPS Diluted | 1.61 | 0.34 | 0.07 | 0.37 | 0.47 |
| Normalized Diluted EPS | 0.95 | 0.14 | 0.02 | 0.24 | 0.19 |
| Average Basic Shares Outstanding | 96.28M | 95.39M | 94.62M | 93.99M | 93.62M |
| Average Diluted Shares Outstanding | 108.47M | 100.45M | 99.14M | 99.11M | 97.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
